Prot #AV-951-12-205: A Phase 2 Randomized, Double-Blind, Crossover, Controlled, Multi-Center, Subject Preference Study of Tivozanib Hydrochloride Versus Sunitinib in the Treatment of Subjects with Metastatic Renal Cell Carcinoma